



ARKG

ARK GENOMIC REVOLUTION ETF

As of March 31, 2019



ARK
INVEST | ETFs

WHY INVEST IN ARKG?

- 1. Exposure to Innovation:** Aims for thematic multi-cap exposure to innovative elements including gene therapy bio-informatics, bio-inspired computing, molecular medicine, and pharmaceutical innovations.
- 2. Growth Potential:** Aims to capture long-term alpha* with low correlation of relative returns to traditional growth strategies and negative correlation to value strategies.
- 3. Tool for Diversification:** Offers a tool for diversification due to little overlap with traditional indices. It can be a complement to traditional value/growth strategies.
- 4. Grounded in Research:** Combines top-down and bottom-up research in its portfolio management to identify innovative companies and convergence across markets.
- 5. Cost Effective:** Provides a lower cost alternative to mutual funds with true active management in an Exchange Traded Fund (ETF) that invests in rapidly moving themes.

BY 2022, THE COST OF SEQUENCING THE DNA OF A FULL HUMAN GENOME SHOULD DROP BELOW \$100. ARK BELIEVES BY THIS TIME, 170 MILLION HUMAN GENOMES SHOULD BE SEQUENCED.

— Source: ARK Investment Management LLC, 2018

FUND DESCRIPTION

“Where Health Care Meets Technology” — Companies within ARKG are focused on and are expected to substantially benefit from extending and enhancing the quality of human and other life by incorporating technological and scientific developments, improvements, and advancements in genomics into their business. These companies may develop, produce or enable:



- 21.0% ● Gene Therapy
- 16.1% ● Molecular Diagnostics
- 14.9% ● Bioinformatics
- 13.1% ● Beyond DNA
- 12.7% ● Instrumentation
- 12.5% ● Targeted Therapeutics
- 7.4% ● Next Generation Oncology
- 1.9% ● Stem Cells
- <1% ● Agricultural Biology

Holdings are subject to change.

FUND DETAILS

Ticker	ARKG
Fund AUM	\$394 Million
Type	Active Equity ETF
CUSIP	00214Q 302
Primary Exchange	NYSE ARCA
Inception Date	10/31/2014
Expense Ratio	0.75%
Typical Number of Holdings	30 - 50
Weighted Avg. Market Cap.	\$35 Billion
Median Market Cap.	\$1.1 Billion
Advisor	ARK Investment Management LLC
Sales Services	Resolute Investment Distributors, Inc.
Fund Distributor	Forside Fund Services, LLC

FUND COMPOSITION AND OBJECTIVE

ARKG is an actively managed Exchange Traded Fund (ETF) that seeks long-term growth of capital. It seeks to achieve this investment objective by investing under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies that are relevant to the Fund’s investment theme of Genomic Revolution. The Fund will be concentrated in issuers in any industry or group of industries in the health care sector, including issuers having their principal business activities in the biotechnology industry.

SECTOR WEIGHTS

Health Care	93.9%
Information Technology	5.9%
Funds	0.2%

PORTFOLIO MANAGER

Catherine D. Wood | Chief Investment Officer

Catherine founded ARK Investment Management in 2014. Previously, she completed twelve years at AllianceBernstein as Chief Investment Officer of Global Thematic Strategies with over \$5 billion in assets under management. Before AllianceBernstein, she worked for eighteen years with Jennison Associates as Chief Economist, Equity Research Analyst, Portfolio Manager, and Director. Catherine started her career in Los Angeles at the Capital Group as an Assistant Economist.

MARKET CAPITALIZATION

Mega	5.9%
Large	17.2%
Medium	21.6%
Small	43.2%
Micro	11.9%


TOP 10 HOLDINGS

SECURITY NAME	WEIGHT
1 INVITAE CORP	10.8%
2 ILLUMINA INC	8.9%
3 INTELLIA THERAPEUTICS INC	7.4%
4 EDITAS MEDICINE INC	6.5%
5 VERACYTE INC	5.8%
6 MEDIDATA SOLUTIONS INC	4.7%
7 CRISPR THERAPEUTICS AG	4.4%
8 NANOSTRING TECHNOLOGIES INC	4.4%
9 BLUEBIRD BIO INC	4.0%
10 COLLECTIS - ADR	3.5%
	60.4%

Holdings are subject to change.

For current portfolio holdings please download "Fund Holdings" as a CSV or PDF at ark-funds.com. Portfolio holdings should not be considered as investment advice or a recommendation to buy, sell or hold any particular security.

GROWTH OF 10,000 USD SINCE INCEPTION



FUND PERFORMANCE

For periods ended March 31, 2019

TOTAL RETURNS	3 Months	YTD	1 Year	3 Years (annualized)	Since Inception (annualized)
ARKG NAV	36.50%	36.50%	30.14%	24.65%	12.70%
ARKG Market Price	37.11%	37.11%	30.27%	24.65%	12.76%
S&P 500 Index (SPX)	13.65%	13.65%	9.50%	13.51%	10.55%
MSCI World Index (M1WO)	12.48%	12.48%	4.01%	10.68%	7.20%
NASDAQ Biotechnology Total Return Index	15.54%	15.54%	5.24%	9.32%	3.28%

For the Fund's most recent month end performance, please visit www.ark-funds.com or call 1-800-679-7759

Past performance does not guarantee future results. The performance data quoted represents past performance and current returns may be lower or higher. The investment return and principal will fluctuate so that an investor's shares when redeemed may be worth more or less than the original cost. Returns for less than one year are not annualized. Net asset value ("NAV") returns are based on the dollar value of a single share of the ETF, calculated using the value of the underlying assets of the ETF minus its liabilities, divided by the number of shares outstanding. The NAV is typically calculated at 4:00 pm Eastern time on each business day the New York Stock Exchange is open for trading. Market returns are based on the trade price at which shares are bought and sold on the NYSE Arca, Inc. using the last share trade. Market performance does not represent the returns you would receive if you traded shares at other times. Total Return reflects reinvestment of distributions on ex-date for NAV returns and payment date for Market Price returns. The market price of the ETF's shares may differ significantly from their NAV during periods of market volatility.

The line graph represents the cumulative performance of a hypothetical \$10,000 investment in ARKG. The returns are net of the ETF's expenses but do not reflect the payment of any brokerage commissions or brokerage costs incurred as a result of buying or selling ARKG shares or trading ARKG shares on an exchange and do not reflect the deduction of taxes to which an investor would be subject as a result of owning or selling shares of ARKG. If they did, the returns would be lower than those shown.

Before investing you should carefully consider the Fund's investment objectives, risks, charges and expenses. This and other information is in the prospectus, a copy of which may be obtained by visiting www.ark-funds.com. Please read the prospectus carefully before you invest.

The principal risks of investing in ARKG: **Equity Securities Risk.** The value of the equity securities the Fund holds may fall due to general market and economic conditions. Foreign Securities Risk. Investments in the securities of foreign issuers involve risks beyond those associated with investments in U.S. securities. **Health Care Sector Risk.** The health care sector may be adversely affected by government regulations and government health care programs, restrictions on government reimbursements for medical expenses, increases or decreases in the cost of medical products and services and product liability claims, among other factors. Many health care companies are heavily dependent on patent protection and intellectual property rights and the expiration of a patent may adversely affect their profitability. **Biotechnology Company Risk.** A biotechnology company's valuation can often be based largely on the potential or actual performance of a limited number of products and can accordingly be greatly affected if one of its products proves, among other things, unsafe, ineffective or unprofitable. Biotechnology companies are subject to regulation by, and the restrictions of, the U.S. Food and Drug Administration, the U.S. Environmental Protection Agency, state and local governments, and foreign regulatory authorities. **Pharmaceutical Company Risk.** Companies in the pharmaceutical industry can be significantly affected by, among other things, government approval of products and services, government regulation and reimbursement rates, product liability claims, patent expirations and protection and intense competition. Detailed information regarding the specific risks of ARKG can be found in the ETF's prospectus. Additional risks of investing in ARKG include Foreign Securities Risk, Information Technology Sector Risk, equity, market, management and non-diversification risks, as well as fluctuations in market value and NAV. An investment in an ETF is subject to risks and you can lose money on your investment in an ETF. There can be no assurance that the ETF will achieve its investment objective. The ETF's portfolio is more volatile than broad market averages. Shares of ARKG are bought and sold at market price (not NAV) and are not individually redeemed from the ETF. ETF shares may only be redeemed directly with the ETF at NAV by Authorized Participants, in very large creation units. There can be no guarantee that an active trading market for ETF shares will develop or be maintained, or that their listing will continue or remain unchanged. Buying or selling ETF shares on an exchange may require the payment of brokerage commissions and frequent trading may incur brokerage costs that detract significantly from investment returns.

The Adviser expects to invest at least 80% of the Fund's assets in Genomics Revolution Companies. However, certain of these companies do not currently derive a substantial portion of their current revenues from genomic-focused businesses and there is no assurance that any company will do so in the future, which may adversely affect the ability of the Fund to achieve its investment objective.

Index Descriptions: The S&P 500® Index is a widely recognized capitalization-weighted index that measures the performance of the large-capitalization sector of the U.S. stock market. The MSCI World Index represents large and mid-cap equity performance across 23 developed markets countries. Returns shown for the MSCI World Index are net of foreign withholding taxes applicable to U.S. investors. Securities in the ETF's portfolio will not match those in any index. The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The NASDAQ Stock Market® (NASDAQ®) that are classified as either biotechnology or pharmaceutical companies, and is a modified market capitalization weighted index. The ETF is benchmark agnostic and corresponding portfolios may have significant non-correlation to any index. Index returns are generally provided as an overall market indicator. You cannot invest directly in an index. Although reinvestment of dividend and interest payments is assumed, no expenses are netted against an index's returns. Index performance information was furnished by sources deemed reliable and is believed to be accurate, however, no warranty or representation is made as to the accuracy thereof and the information is subject to correction.

*Alpha is a measure of performance on a risk-adjusted basis. Alpha takes the volatility (price risk) of a fund and compares its risk-adjusted performance to a benchmark index. The excess return of the fund relative to the return of the benchmark index is a fund's alpha. Beta is the current measure of a portfolio's risk in relation to the market or a benchmark.

Foreside Fund Services LLC, distributor.

NOT FDIC INSURED — NO BANK GUARANTEE — MAY LOSE VALUE

For information regarding ARK's ETFs, please contact our sales partner, Resolute Investment Distributors: 1-800-679-7759

ARK Investment Management LLC
3 E 28th Street, 7th Floor, New York, NY 10016

efs@ark-invest.com | ark-funds.com